title: Crohn's disease successfully treated with infliximab in a patient receiving hemodialysis: case report and review of the literature.
abstract: There is limited information in the use of antitumor necrosis factor α, infliximab, in patients on hemodialysis. In Crohn's disease (CD), only 3 cases are reported.A 76-year-old man on hemodialysis for renal failure caused by immunoglobulin A nephropathy developed diarrhea and abdominal pains. A marked edema was observed in the pretibia and ankle. An increase of C-reactive protein (CRP) and erythrocyte sedimentation rate, hypoalbuminemia, hypocholesterolemia, and moderate anemia was found. Ultrasonography and computed tomography (CT) found wall thickness in the left colon. Sigmoidoscopy revealed multiple ulcers in the sigmoid colon and noncaseating epithelioid granuloma was found in the biopsy specimen. Barium enema study exhibited collar button signs and longitudinal ulcers in the left colon.A severe form of CD was diagnosed. Metronidazole seemed to decrease CRP but was ineffective in ameliorating diarrhea. Infliximab rather than steroid hormone was chosen for the treatment. Standard induction therapy with infliximab was initiated. Symptoms rapidly improved then disappeared. CD activity index decreased from 747 to a remission level of 134 after 2 infusions of infliximab. Scheduled maintenance infliximab therapy was administered after the induction therapy. Ultrasonography and CT showed a disappearance of the wall thickness of the colon. Adverse reactions were not observed.Infliximab was effective and safe in a patient with CD on hemodialysis. Our case has added additional literature in accordance with previous reports supporting infliximab as effective and safe in patients on hemodialysis.
authors.affiliation: Division of Gastroenterology (MC, ST, TT, KN, MK), Division of Urology (YM, TI), and Division of Cardiology (TS), Akita City Hospital; Akita South Clinic (TN), Akita City, Japan.
authors.forename: Mitsuro
authors.initials: M
authors.lastname: Chiba
authors.forename: Satoko
authors.initials: S
authors.lastname: Tsuda
authors.forename: Tsuyotoshi
authors.initials: T
authors.lastname: Tsuji
authors.forename: Kunio
authors.initials: K
authors.lastname: Nakane
authors.forename: Masafumi
authors.initials: M
authors.lastname: Komatsu
authors.forename: Yoshiko
authors.initials: Y
authors.lastname: Miura
authors.forename: Toshiya
authors.initials: T
authors.lastname: Ishida
authors.forename: Toru
authors.initials: T
authors.lastname: Shibahara
authors.forename: Tadashi
authors.initials: T
authors.lastname: Nishimoto
mesh_terms: D000368:Aged; D000894:Anti-Inflammatory Agents, Non-Steroidal / Q000627:therapeutic use*; D000911:Antibodies, Monoclonal / Q000627:therapeutic use*; D003424:Crohn Disease / Q000150:complications / Q000188:drug therapy*; D006801:Humans; D000069285:Infliximab; D008297:Male; D006435:Renal Dialysis; D051436:Renal Insufficiency, Chronic / Q000150:complications / Q000628:therapy*
chemical_list: D000894:Anti-Inflammatory Agents, Non-Steroidal; D000911:Antibodies, Monoclonal; D000069285:Infliximab
references.citation: Clin Exp Rheumatol. 2010 May-Jun;28(3):440
references.pmid: 20576230
references.citation: N Engl J Med. 2010 Apr 15;362(15):1383-95
references.pmid: 20393175
references.citation: Am J Gastroenterol. 2013 Aug;108(8):1268-76
references.pmid: 23649185
references.citation: Rheumatology (Oxford). 2006 Mar;45(3):357-9
references.pmid: 16368727
references.citation: Am J Roentgenol Radium Ther Nucl Med. 1971 Oct;113(2):325-34
references.pmid: 5098634
references.citation: Ann Intern Med. 2001 Jul 3;135(1):27-31
references.pmid: 11434729
references.citation: Dig Dis Sci. 2007 Jun;52(6):1481-4
references.pmid: 17429728
references.citation: Gastroenterology. 2012 Jan;142(1):46-54.e42; quiz e30
references.pmid: 22001864
references.citation: J Gastrointestin Liver Dis. 2013 Sep;22(3):333-6
references.pmid: 24078992
references.citation: Lancet. 2011 Jul 2;378(9785):31-40
references.pmid: 21705069
references.citation: Inflamm Bowel Dis. 2009 Aug;15(8):1121-2
references.pmid: 18942761
references.citation: Colorectal Dis. 2011 Mar;13(3):341
references.pmid: 20082632
references.citation: Gut. 2009 Aug;58(8):1033-9
references.pmid: 19592682
references.citation: Am J Gastroenterol. 2009 Feb;104(2):465-83; quiz 464, 484
references.pmid: 19174807
references.citation: Aliment Pharmacol Ther. 2012 Aug;36(4):312-23
references.pmid: 22725726
references.citation: QJM. 2010 Dec;103(12):917-28
references.pmid: 20802008
references.citation: Am J Gastroenterol. 2002 Dec;97(12):2962-72
references.pmid: 12492177
references.citation: Rheumatol Int. 2005 Aug;25(6):406-10
references.pmid: 15309501
references.citation: Inflamm Bowel Dis. 2012 Jun;18(6):1057-63
references.pmid: 21953829
references.citation: Clin Rheumatol. 2010 Dec;29(12):1455-9
references.pmid: 20490588
references.citation: Gut. 2006 Apr;55(4):505-9
references.pmid: 16188920
references.citation: J Rheumatol. 2002 Mar;29(3):636-7
references.pmid: 11908584
references.citation: Gastrointest Radiol. 1979 Jan 30;4(1):79-84
references.pmid: 761749